Objectives The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents. Methods We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey. Results The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsychotics (AAP). The first-line medications selected for these children were aripiprazole (treatme f choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic episodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, andmonotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were selected as first-line medications for these adolescents. First-line pharmacotherapeutic strategiesfor depressive episodes in adolescents were a combination of MS and an AAP, monotherapywith MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for thedepressive episodes in adolescents at high risk for bipolar disorder were a combination of MSand AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, andrisperidone were selected as first-line medications for the treatment of depressive episodes inadolescents with bipolar disorder. Conclusion It is expected that the present KMAP-BP 2022: children and adolescents will givethe direction and be usefully applied by clinicians to treat children and adolescents with bipolardisorders.